Table 2

The relationship between CD44v6 and integrin-β1 mRNA expression and clinical pathological features of patients with PC
Pathological features N CD44v6 mRNA expression P value Integrin-β1 mRNA expression P value
High Low High Low
Sex 0.238 0.132
  Male 27 12 (54.5%) 15 (45.5%) 13 (48.1%) 14 (51.9%)
  Female 27 10 (37.0%) 17 (63.0%) 8 (29.6%) 19 (70.4%)
Age 0.921 0.810
  ≤60 24 10 (41.7%) 14 (58.3%) 9 (37.5%) 15 (62.5%)
  >60 30 12 (40.0%) 18 (60.0%) 12 (40.0%) 18 (60.0%)
Tumor location 0.235 0.241
  Head and Body PC 34 12 (35.3%) 22 (64.7%) 14 (41.2%) 20 (58.8%)
  Tail PC 20 10 (50.0%) 10 (50.0%) 7 (35.0%) 13 (65.0%)
Clinical stages 0.016 0.023
  I+II 21 4 (19.0%) 17 (81.0%) 4 (18.2%) 18 (81.8%)
  III+IV 33 18 (54.5%) 15 (45.5%) 17 (53.1%) 15 (46.9%)
Tumor differentiation <0.01 0.067
  Poorly and Moderately 33 7 (21.2%) 26 (78.8%) 9 (29.0%) 22 (71.0%)
  Highly 21 15 (71.4%) 6 (28.6%) 12 (52.2%) 11 (47.8%)
Tumor size (diameter) 0.187 0.114
  ≤4 cm 25 8 (32.0%) 17 (68.0%) 7 (28.0%) 18 (72.0%)
  >4 cm 29 14 (48.3%) 15 (51.7%) 14 (48.3%) 15 (51.7%)
LNM 0.028 0.034
  Negative 20 4 (20.0%) 16 (80.0%) 6 (23.1%) 20 (76.9%)
  Positive 34 18 (52.9%) 16 (47.1%) 15 (53.6%) 13 (46.4%)
Liver metastasis 0.020 0.028
  Negative 24 5 (20.8%) 19 (79.2%) 5 (20.8%) 19 (79.2%)
  Positive 30 17 (56.7%) 13 (43.3%) 16 (53.3%) 14 (46.7%)
CA199(U/ml) 0.887 0.165
  ≤1000 18 7 (38.9%) 11 (61.1%) 5 (27.8%) 13 (72.2%)
  >1000 36 15 (41.7%) 21 (58.3%) 16 (44.4%) 20 (55.6%)
KPS 0.665 0.841
  ≤80 25 11 (44.0%) 14 (56.0%) 10 (40.0%) 15 (60.0%)
  >80 29 11 (37.9%) 18 (62.1%) 11 (37.9%) 18 (62.1%)

Zhou et al.

Zhou et al. Diagnostic Pathology 2013 8:146   doi:10.1186/1746-1596-8-146

Open Data